DRI buys Biogen's Benlysta royalties
This article was originally published in Scrip
Executive Summary
Biogen Idec has sold its royalty stream for lupus drug Benlysta (belimumab) to DRI Capital in exchange for larger payments over a shorter period which "allows us to accelerate payments that would otherwise have been spread over a longer time period as we prepare for multiple pivotal trial data readouts and potential product launches", said Biogen.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.